ImCheck’s “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of
Institut Jules BordetThe Institute for Cancer Research and Royal MarsdenInstitut Paoli-CalmettesVall d’Hebron Institute of OncologyCHU de NantesYale University Cancer CenterImcheck TherapeuticsIlife consultingCRCMSpringer Verlagjournal for immunotherapy of cancer...
P. PeterlinDepartment of Hematology, University Hospital of Nantes (Hôtel-Dieu-CHU de Nantes), Nantes, FranceK. LemmensMedical, ImCheck Therapeutics SAS, Marseille, FranceA. de GassartTranslational Research, ImCheck Therapeutics SAS, Marseille, FranceP. Brune...